Orchid Pharma's new antibiotic 'Exblifeb' gets European Medicines Agency approval

Written By :  Kajal Rajput
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-01-30 08:45 GMT   |   Update On 2024-03-22 11:58 GMT
Advertisement

New Delhi: Orchid Pharma on Tuesday said it has received approval from the European Medicines Agency for marketing its antibiotic 'Exblifeb'. The Chennai-based firm said Exblifeb incorporates Enmetazobactam, ''the first completely invented-in-India Beta Lactamase inhibitor'' and it is designed to address the global challenge of antimicrobial resistance (AMR).

Exblifeb' demonstrates remarkable efficacy in treating complicated urinary tract infections (UTI), pneumonia, and bacteremia caused by extended spectrum beta-lactamase producing pathogens, Orchid Pharma said in a regulatory filing.

Advertisement

Also Read:Orchid Pharma to raise Rs 500 crore from institutional investors

During clinical trials, 'Exblifeb' exhibited superior performance compared to the current go-to drug, (Piperacillin + Tazobactam), it added.

"With the potential to save thousands of lives globally, this approval by EMA is a testament to Indian ingenuity. It is also a matter of great pride that as the pharmacy of the world, India has now developed a new drug for the first time," Orchid Pharma Managing Director Manish Dhanuka.

Enmetazobactam was invented in India by Orchid and then out-licensed to Allecra Therapeutics for further development.

Original news source: https://www.ptinews.com/story/business/orchid-pharma-s-new-antibiotic-exblifeb-gets-european-medicines-agency-approval/1251989 

Also Read:Orchid Pharma to transfer NPNC formulations division to JV with Bionpharma

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News